isradipine has been researched along with Prostatic Hyperplasia in 1 studies
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosenthal, E | 1 |
| Shapiro, E | 1 |
| Lepor, H | 1 |
1 other study available for isradipine and Prostatic Hyperplasia
| Article | Year |
|---|---|
Characterization of 1,4, dihydropyridine calcium channel binding sites in the human prostate.
Topics: Binding Sites; Calcium Channel Blockers; Calcium Channels; Humans; In Vitro Techniques; Isradipine; | 1990 |